Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus

Journal of Diabetes

Volumn 8, Issue 3, 2016, Pages 345-353

  Ning, Guang ^a   Wang, Weiqing ^a   Li, Ling ^c   Ma, Jianhua ^d   Lv, Xiaofeng ^e   Yang, Ming ^b   Wang, Wei ^b   Woloschak, Michael ^f,g   Lukashevich, Valentina ^f   Kothny, Wolfgang ^f  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b Beijing Novartis Pharma ^*  (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f NOVARTIS PHARMA AG   (Switzerland)

^g SANOFI   (France)

Author keywords

Add on insulin; Dipeptidyl peptidase 4; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; NITRILE; PYRROLIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; ASIAN; BODY WEIGHT DISORDER; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; ANALYSIS; ASIA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADAMANTANE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES; YOUNG ADULT;

EID: 84964040247     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12303     Document Type: Article

References (23)

1. International Diabetes Federation (IDF). Diabetes Atlas, 6th edn. IDF, Brussels, 2013.
2. Wong CSM, Wang HHX, Kwan MWM etal. Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: A systematic review. PLoS ONE. 2014; 9: e90963.
3. Lin JD, Chen YL, Hsu CH etal. Beta-cell function and insulin sensitivity at various degrees of glucose tolerance in Chinese subjects. Diabetes Res Clin Pract. 2013; 10: 391-397.
4. Chan JCN, Malik V, Jia W etal. Diabetes in Asia: Epidemiology, risk factors and pathophysiology. JAMA. 2009; 301: 2129-2140.
5. Yoon KH, Lee JH, Kim JW etal. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368: 1681-1688.
6. Herman WH. Do race and ethnicity impact hemoglobin A1c independent of glycemia? J Diabetes Sci Technol. 2009; 3: 656-660.
7. Chinese Diabetes Society. China guideline for type 2 diabetes. Chin J Diabetes. 2012; 20 (Suppl.) S1-37.
8. Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response. Diabetes Care. 2013; 36: 1789-1796.
9. Chiu M, Austin PC, Manuel DG, Shah BR, Tu JV. Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. Diabetes Care. 2011; 34: 1741-1748.
10. 1chieve study. Diabetes Res Clin Pract. 2011; 94: 352-363.
11. Mohammed M. An audit on diabetes management in Asian patients treated by specialists: The Diabcare-Asia 1998 and 2003 studies. Curr Med Res Opin. 2008; 24: 507-514.
12. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013; 15: 252-257.
13. Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes. 2013; 4: 151-156.
14. Mu YM, Misra A, Adam JMF etal. Managing diabetes in Asia: Overcoming obstacles and the role of DPP-IV inhibitors. Diabetes Res Clin Pract. 2012; 95: 179-188.
15. Schweizer A, Foley JE, Kothny W, Ahrén B. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Vasc Health Risk Manag. 2013; 9: 57-64.
16. Phung OJ, Sobieraj DM, Enjel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetes Obes Metab. 2014; 16: 410-417.
17. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
18. Khunti K, Srinivasan BT, Shutler S, Davies MJ. Effect of insulin glargine on glycaemic control and weight in obese and non-obese people with type 2 diabetes: Data from the AT.LANTUS trial. Diabetes Obes Metab. 2010; 12: 683-688.
19. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011; 13: 775-783.
20. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia. Diabetes Obes Metab. 2009; 11: 1145-1152.
21. Pan C, Yang W, Barona JP etal. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: A 24-week, double-blind, randomized trial. Diabet Med. 2008; 4: 435-441.
22. Pan C, Xing X, Han P etal. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012; 14: 737-744.
23. Yang W, Xing X, Lv X etal. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus. J Diabetes. 2015; 7: 174-181.